5 Minutes
Imagine finding a key to a locked door in a different house. That is what a team of US researchers appears to have done: two drugs already used in oncology reduced hallmark Alzheimer’s damage in mouse brains and improved memory performance.
The medications are letrozole, typically prescribed for hormone-driven breast cancer, and irinotecan, a chemotherapy drug used in colon and lung cancer. Both are approved by US regulators, which shortens one barrier to testing them in people. Yet promise on the bench is not the same as proof in patients. Still, the results are striking enough to force a closer look.
The experimental team began with a difficult question: which existing drugs might reverse the complex gene-expression changes Alzheimer’s causes in the brain? They turned to large molecular databases and real-world clinical records to search for answers. What emerged was a pair of candidates that, when combined, appeared to hit different vulnerable cell types and reduce the disease’s signature pathology.
The application of letrozole and irinotecan reduced the level of tau proteins (light green) in mouse brains.
From data mining to mouse behavior
The researchers used gene-expression profiles from brains affected by Alzheimer’s and queried the Connectivity Map, a public resource that links drugs to the gene changes they induce. The idea is simple in concept: find compounds that flip disease-associated expression patterns back toward normal. Then cross-check those computational hits against clinical records to see whether patients exposed to the candidate drugs showed any signal of reduced Alzheimer’s risk.
The computational biologist Marina Sirota of UC San Francisco, who led part of the work, explained that their tools were designed to tackle Alzheimer’s complexity by integrating multiple data sources. The cross-validation mattered. Independent datasets converged on the same drug targets, and those signals held up when tested in a genetic mouse model of Alzheimer’s.
In the lab, the drugs were administered in combination. The result: a substantial reduction in tau aggregates, the sticky protein tangles associated with neuronal dysfunction, and measurable improvements in learning and memory tasks in the mice. The team attributes this synergy to cell-type specificity. Letrozole appeared to act primarily on neurons, while irinotecan influenced glial cells, such as microglia or astrocytes, which are increasingly recognized as key players in neurodegeneration.
"Alzheimer’s is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health," said neuroscientist Yadong Huang of UC San Francisco and the Gladstone Institutes. Traditional drug discovery often targets a single protein. This study points toward combination therapies that can address multiple disturbed pathways at once.
That approach aligns with an emerging view in neurotherapeutics: disease-modifying success may require coordinated modulation of neurons, immune responses, and vascular or metabolic factors in the brain.
Expert Insight
Dr. Leila Moreno, a neurologist and translational researcher unaffiliated with the study, notes: "Repurposing approved oncology agents is attractive because we already know a lot about dosing and toxicities. But cancer drugs can carry serious side effects. Translating these findings will depend on whether effective, lower-risk regimens can be identified for older adults with Alzheimer’s."
Moreno emphasizes the practical hurdles. "Mouse models are useful, but they do not capture the full complexity of human Alzheimer’s, especially when it comes to ageing, comorbidities, and long-term tolerance of chemotherapy agents. Clinical trials will need careful design and patient selection."
Side effects are not a minor detail. Letrozole modulates hormones and can cause bone density loss and other effects; irinotecan is associated with gastrointestinal toxicity and myelosuppression. Any repurposing strategy must weigh these risks against potential cognitive benefits and explore whether lower doses or intermittent schedules maintain efficacy while improving safety.
The research team proposes clinical trials as the next step, possibly with stratification based on an individual’s gene-expression profile. Personalization could narrow treatment to patients most likely to benefit, reducing unnecessary exposure to risk for those unlikely to respond.
More than 55 million people worldwide currently live with Alzheimer’s, a figure projected to rise sharply as populations age. If existing drugs can be redeployed safely and effectively, the public-health impact would be enormous. Still, the path from mouse to medicine is long and littered with setbacks.
The study has been published in Cell. It marks a careful, data-driven attempt to repurpose well-characterized drugs against a disease that has defied many single-target therapies. Whether this particular combination will survive the crucible of clinical testing remains to be seen, but the method—integrating molecular signatures with real-world patient data—offers a pragmatic route to uncovering unexpected therapeutic leads.
Source: sciencealert
Leave a Comment